Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Non-Current Liabilities: 2020-2025

Historic Total Non-Current Liabilities for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $76.2 million.

  • Lyell Immunopharma's Total Non-Current Liabilities fell 10.35% to $76.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year decrease of 10.35%. This contributed to the annual value of $104.8 million for FY2024, which is 14.62% up from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Total Non-Current Liabilities is $76.2 million, which was down 8.79% from $83.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Total Non-Current Liabilities ranged from a high of $207.0 million in Q2 2021 and a low of $76.2 million during Q3 2025.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $90.1 million (2025), whereas its average is $89.4 million.
  • Per our database at Business Quant, Lyell Immunopharma's Total Non-Current Liabilities slumped by 50.31% in 2023 and then grew by 14.62% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Total Non-Current Liabilities (Quarterly) stood at $193.1 million in 2021, then plummeted by 48.10% to $100.2 million in 2022, then declined by 8.77% to $91.4 million in 2023, then grew by 14.62% to $104.8 million in 2024, then declined by 10.35% to $76.2 million in 2025.
  • Its last three reported values are $76.2 million in Q3 2025, $83.5 million for Q2 2025, and $90.1 million during Q1 2025.